Clinical Trials Logo

Epilepsies, Partial clinical trials

View clinical trials related to Epilepsies, Partial.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06309966 Recruiting - Focal Epilepsy Clinical Trials

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

RISE 3
Start date: May 13, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

NCT ID: NCT06173076 Recruiting - Clinical trials for Autoimmune Encephalitis

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Start date: May 18, 2022
Phase:
Study type: Observational

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases. So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

NCT ID: NCT06132893 Recruiting - Focal Epilepsy Clinical Trials

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

RISE 2
Start date: March 14, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

NCT ID: NCT05981755 Recruiting - Focal Epilepsy Clinical Trials

Breathing Rescue for SUDEP Prevention

BreatheS
Start date: July 31, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.

NCT ID: NCT05951244 Recruiting - Clinical trials for Drug Resistant Epilepsy

Cathodal Transcranial Direct Current Stimulation in Patients With Drug-resistant Focal Epilepsy

Start date: April 3, 2023
Phase: N/A
Study type: Interventional

The basis of this project is the application of cathodal tDCS in patients with drug-resistant focal epilepsy including patients whose seizures persist after epilepsy surgery, who rejected epilepsy surgery, and/or who are not suitable for surgery. For this purpose, 5-day consecutive cathodal electrical stimulation sessions will be used with personalized electrode montage according to the patient's seizure focus. In this context, the changes in seizures frequency and epileptic discharges will be examined for the first week and 12th week after the tDCS sessions through the seizure diary of the patients and the electroencephalogram (EEG) recordings to be taken. In addition, changes in cognitive functions, mood, and quality of life will be examined in patients after the intervention.

NCT ID: NCT05886205 Recruiting - Clinical trials for Refractory Focal Epilepsy

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy

Start date: June 5, 2023
Phase: Early Phase 1
Study type: Interventional

Evaluate the safety, tolerability, and preliminary efficacy of GD-iEXo-002 nasal drops in the treatment of focal refractory epilepsy

NCT ID: NCT05673915 Recruiting - Focal Epilepsy Clinical Trials

Study of Transcranial Direct Current Stimulation to Treat Epilepsy

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.

NCT ID: NCT05503264 Recruiting - Clinical trials for NMDAR Autoimmune Encephalitis

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Cielo
Start date: September 27, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.

NCT ID: NCT05419180 Recruiting - Clinical trials for Pharmacoresistant Focal Epilepsies

Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

Start date: October 13, 2022
Phase: Phase 4
Study type: Interventional

This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.

NCT ID: NCT05278221 Recruiting - Focal Epilepsy Clinical Trials

TMS Combined With EEG/EMG as a Biomarker Predicting Antiepileptic Drug Response

BIOEPI
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Ιn the present study (BIOEPI), the following three hypotheses will be investigated: 1. The proposed TMS-EEG / EMG protocol (which includes software for calculating the cerebral cortex stimulation threshold) in combination with advanced signal analysis and data mining methods will allow the detection of the effect of antiepileptic drugs (AED) with different mechanisms of action (lacosamide & brivaracetam) in the Central Nervous System under healthy and pathological conditions (Epilepsy). 2. AED-induced changes in selected TMS-EEG / EMG features predict the clinical response of individual epileptic patients to AED. 3. AED-induced changes in selected TMS-EEG / EMG features may predict cognitive side effects.